Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
McKinsey
Accenture
Johnson and Johnson
Express Scripts
Fuji
Medtronic
US Department of Justice
Farmers Insurance
Cipla

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,328,994

« Back to Dashboard

Summary for Patent: 6,328,994
Title: Orally disintegrable tablets
Abstract:An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 .mu.m or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration.
Inventor(s): Shimizu; Toshihiro (Itami, JP), Morimoto; Shuji (Suita, JP), Tabata; Tetsuro (Suita, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:09/355,781
Patent Claim Types:
see list of patent claims
Dosage form; Composition; Formulation;

Drugs Protected by US Patent 6,328,994

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa DEXILANT SOLUTAB dexlansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 208056-001 Jan 26, 2016 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Takeda Pharms Usa PREVACID lansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 021428-001 Aug 30, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Takeda Pharms Usa PREVACID lansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 021428-002 Aug 30, 2002 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,328,994

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan10-135472May 18, 1998
Japan10-219266Aug 03, 1998
Japan10-222151Aug 05, 1998
Japan10-344810Oct 29, 1998
Japan11-005144Jan 12, 1999
Japan11-015851Jan 25, 1999
PCT Information
PCT FiledMay 17, 1999PCT Application Number:PCT/JP99/02548
PCT Publication Date:November 25, 1999PCT Publication Number: WO99/59544

Non-Orange Book US Patents Family Members for Patent 6,328,994

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,431,942 Orally disintegrable tablets ➤ Sign Up
7,875,292 Orally disintegrable tablets ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,328,994

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 348601 ➤ Sign Up
Australia 3731699 ➤ Sign Up
Canada 2323680 ➤ Sign Up
Canada 2587022 ➤ Sign Up
China 1195500 ➤ Sign Up
China 1311669 ➤ Sign Up
Germany 69934505 ➤ Sign Up
Denmark 1121103 ➤ Sign Up
Denmark 1736144 ➤ Sign Up
Denmark 2263660 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Argus Health
Cantor Fitzgerald
Covington
QuintilesIMS
US Army
Accenture
Medtronic
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot